Genmab A/S
Denmark
435 articles about Genmab A/S
-
Notice to Convene the Annual General Meeting of Genmab A/S
2/24/2022
COPENHAGEN, Denmark; February 24, 2022 – Genmab A/S summons the Annual General Meeting on Tuesday, March 29, 2022, at 2:00 PM CEST at the Copenhagen Marriott Hotel, KalvebodBrygge 5, DK-1560 Copenhagen V, Denmark.
-
Genmab Publishes 2021 Annual Report
2/16/2022
Genmab A/S announced the publication of its Annual Report for 2021.
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021
1/25/2022
Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab) as reported by Johnson & Johnson were USD 6,023 million in 2021.
-
Genmab and Synaffix Enter into License Agreement for ADC Technology
1/4/2022
Genmab A/S (Nasdaq: GMAB) and Synaffix B.V., announced today that Genmab and Synaffix have signed a license agreement providing Genmab broad access to Synaffix’s ADC technologies.
-
The approval was based on Phase II data from the PLEIADES study that showed patients treated with the combination therapy generated an overall response rate of 84.8%.
-
Genmab Announces Financial Results for the First Nine Months of 2021
11/10/2021
Genmab Announces Financial Results for the First Nine Months of 2021
-
Shares of Xencor, Inc. are down nearly 6% after the company announced Novartis terminated its rights to develop vibecotamab, a CD123 x CD3 blood cancer bispecific.
-
Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)
11/4/2021
Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)
-
Genmab Improves its 2021 Financial Guidance
11/4/2021
Genmab A/S announced that it is improving its 2021 financial guidance published on August 11, 2021.
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
10/19/2021
Copenhagen, Denmark; October 19, 2021 – Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous formulation,as reported by Johnson & Johnson were USD 1,580million in the third quarter of 2021.
-
The U.S. FDA is kicking off the month of October with a number of PDUFA dates and an advisory committee meeting. Read on for more details.
-
Clinical Catch-Up: September 20-24
9/27/2021
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look. -
Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
9/20/2021
Seagen Inc. and Genmab A/S announced that the U.S. Food and Drug Administration has granted accelerated approval to TIVDAK™, the first and only approved antibody-drug conjugate for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
-
Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
9/19/2021
Seagen Inc. and Genmab A/S presented interim data from two cohorts of the phase 1b/2 innovaTV 205 multi-cohort, open-label trial of tisotumab vedotin in recurrent or metastatic cervical cancer at the European Society for Medical Oncology Virtual Congress 2021 as part of a featured mini oral presentation.
-
Approximately 14,000 American women are expected to be diagnosed with invasive cervical cancer in 2021, and more than 4,000 are expected to succumb to the disease.
-
Genmab Announces Financial Results for the First Half of 2021
8/11/2021
Genmab Announces Financial Results for the First Half of 2021
-
Major Shareholder Announcement for Genmab A/S
7/21/2021
Genmab A/S announces under reference to Section 30 of the Danish Capital Markets Act that Artisan Partners LimitedPartnership has informed us that, as of July 16, 2021, Artisan Partners Limited Partnershipholds the voting rights to 3,261,591 sharesin Genmab A/S, which amounts to 4.97% of the share capital and voting rights in Genmab A/S.
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021
7/21/2021
Copenhagen, Denmark; July 21, 2021 – Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous formulation,as reported by Johnson & Johnson were USD 1,433 million in the second quarter of 2021.
-
Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
6/22/2021
Genmab A/S (Nasdaq:GMAB)announced today that the European Commission (EC) has granted marketing authorization for the daratumumab subcutaneous (SC) formulation(daratumumab and hyaluronidase-fihj), known as DARZALEX® SCin the European Union, in combination with bortezomib, cyclophosphamide, and dexamethasone (VCd) for the treatment of adult patients with newly diagnosed systemiclight-chain (AL) amyloidosis.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.